Home /Biblio

Biblio

Found 399 results
Author Keyword Title Type [ Year(Asc)]
2016
P. Harter, Johnson, T., Berton-Rigaud, D., Park, S. - Y., Friedlander, M. Leonard, Del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C. - F., and du Bois, A., “BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.”, Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.
J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., “Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
D. J. Pulford, Harter, P., Floquet, A., Barrett, C., Suh, D. Hoon, Friedlander, M. Leonard, Arranz, J. Angel, Hasegawa, K., Tada, H., Vuylsteke, P., Mirza, M. R., Donadello, N., Scambia, G., Johnson, T., Cox, C., Chan, J. K., Imhof, M., Herzog, T. J., Calvert, P., Wimberger, P., Berton-Rigaud, D., Lim, M. Cheol, Elser, G., Xu, C. - F., and Bois, Adu, “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.”, BMC Med Ethics, vol. 17, no. 1, p. 63, 2016.
A. M. Angarita, Johnson, C. Alonia Lil, Fader, A. Nickles, and Christianson, M. S., “Fertility preservation: A key survivorship issue for young women with cancer ”, Frontiers in Oncology , vol. 6, no. 102, 2016.
S. Lheureux, Karakasis, K., Harter, P., Scott, C., Bacon, M., Bryce, J., Le Fur, N., Pujade-Lauraine, E., and Oza, A. M., “Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.”, Gynecol Oncol, vol. 140, no. 1, p. 94, 2016.
K. Katherine, Julia, B., Valerie, B., Oza, A. M., and Stephanie, L., “Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention ”, Frontiers in Oncology , vol. 6, no. 00119 , 2016.
Y. Ikeda, Furusawa, A., Kitagawa, R., Tokinaga, A., Ito, F., Ukita, M., Nomura, H., Yamagami, W., Tanabe, H., Mikami, M., Takeshima, N., and Yaegashi, N., “Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.”, J Gynecol Oncol, vol. 27, no. 3, p. e29, 2016.
K. Harano, Hirakawa, A., Yunokawa, M., Nakamura, T., Satoh, T., Nishikawa, T., Aoki, D., Ito, K., Ito, K., Nakanishi, T., Susumu, N., Takehara, K., Watanabe, Y., Watari, H., and Saito, T., “Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.”, Int J Clin Oncol, vol. 21, no. 1, pp. 168-76, 2016.
L. Brotto, Brundage, M., Hoskins, P., Vergote, I. B., Cervantes, A., Casado, H. A., Poveda, A. M., Eisenhauer, E., and Tu, D., “Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.”, Support Care Cancer, vol. 24, no. 3, p. 1249, 2016.
S. Temkin, Tanner, E. J., Dewdney, S., and Minasian, L. M., “Reducing overtreatment in gynecologic oncology: the case for less in endometrial and ovarian cancer”, Frontiers in Oncology , vol. 6, no. 00118 , 2016.
A. du Bois, Kristensen, G. B., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I. B., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G., Meier, W., Nicoletto, M. O., Bjørge, L., Lortholary, A., Sailer, M. Oliver, Merger, M., and Harter, P., “Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet Oncol, vol. 17, no. 1, p. 89, 2016.
J. K. Chan, Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H., and Monk, B. J., “Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.”, N Engl J Med, vol. 374, no. 8, p. 748, 2016.
2015
F. T. Roncolato, O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P. P., Oza, A. M., Åvall-Lundqvist, E., Berek, J. S., Sjoquist, K. Marie, Gillies, K., Butow, P., Stockler, M. R., King, M. Trudy, and Friedlander, M. Leonard, “Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The GCIG Symptom Benefit Study (SBS).”. 2015.
A. M. Poveda, Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I. B., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., and Pujade-Lauraine, E., “Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.”, J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.
R. T. Penson, Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H., and Tewari, K. S., “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).”, Lancet Oncol, vol. 16, no. 3, pp. 301-11, 2015.
S. Mahner, Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell'Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., Vergote, I. B., Vasey, P. A., Pujade-Lauraine, E., Gladieff, L., and Ferrero, A., “Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.”, Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.
D. K. Gaffney, Suneja, G., Ryu, S. Young, McCormick, M., Plante, M., Mileshkin, L. R., Small, W., Bacon, M., Stuart, G. C. E., and Kitchener, H. C., “The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup.”, Int J Radiat Oncol Biol Phys, vol. 92, no. 3, pp. 506-8, 2015.
E. Despierre, Vergote, I. B., Anderson, R., Coens, C., Katsaros, D., Hirsch, F. R., Boeckx, B., Varella-Garcia, M., Ferrero, A., Ray-Coquard, I., Berns, E. M. J. J., Casado, A., Lambrechts, D., and Jimeno, A., “Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.”, Target Oncol, vol. 10, no. 4, pp. 583-96, 2015.
T. Iwata, Hasegawa, T., Ochiai, K., Takizawa, K., Umezawa, S., Kuramoto, H., Ohmura, M., Kubushiro, K., Arai, H., Sakamoto, M., Motoyama, T., Watanabe, K., and Aoki, D., “Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.”, Reprod Sci, vol. 22, no. 12, pp. 1509-15, 2015.
C. Khoon Lee, Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A. - C., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I. B., Scambia, G., Ferrero, A., Harter, P., Pujade-Lauraine, E., and Friedlander, M. Leonard, “Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.”, Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.
A. Floquet, Vergote, I. B., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., Calvert, P., Herzog, T. J., Meier, W., Kim, J. - W., Del Campo, J. M., Friedlander, M. Leonard, Pisano, C., Isonishi, S., Crescenzo, R. J., Barrett, C., Wang, K., Mitrica, I., and du Bois, A., “Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.”, Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
A. M. Oza, Cook, A. D., Pfisterer, J., Embleton, A. C., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T. - W., Rustin, G. J. S., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A. M., Jayson, G. C., Stark, D., Swart, A. Marie, Farrelly, L., Kaplan, R. S., Parmar, M. K. B., and Perren, T. J., “Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.”, Lancet Oncol, vol. 16, no. 8, p. 936, 2015.
2014
F. Trillsch, Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., de Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Baumann, K. H., Keyver-Paik, M. D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schröder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S., and du Bois, A., “Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study”, Ann Oncol, vol. 25, pp. 1320-7, 2014.
E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.”, J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
S. Pignata, Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., Cormio, G., Sorio, R., Cavazzini, M. G., Ferrandina, G., Breda, E., Murgia, V., Sacco, C., Cinieri, S., Salutari, V., Ricci, C., Pisano, C., Greggi, S., Lauria, R., Lorusso, D., Marchetti, C., Selvaggi, L., Signoriello, S., Piccirillo, M. C., Di Maio, M., Perrone, F., Cancer, M. Italian Tr, Sein, Gd'Investig, Oncology, M. Negri Gyne, Groups, E. Network of, and Investigators, G. Cancer Int, “Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial”, Lancet Oncol, vol. 15, pp. 396-405, 2014.

Pages